DE2510325A1 - Mittel zur prophylaxe und bekaempfung von harninfektionen - Google Patents
Mittel zur prophylaxe und bekaempfung von harninfektionenInfo
- Publication number
- DE2510325A1 DE2510325A1 DE19752510325 DE2510325A DE2510325A1 DE 2510325 A1 DE2510325 A1 DE 2510325A1 DE 19752510325 DE19752510325 DE 19752510325 DE 2510325 A DE2510325 A DE 2510325A DE 2510325 A1 DE2510325 A1 DE 2510325A1
- Authority
- DE
- Germany
- Prior art keywords
- urine
- compound
- administered
- bromophenyl
- acetamidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000011321 prophylaxis Methods 0.000 title claims description 3
- 210000002700 urine Anatomy 0.000 title description 27
- 208000015181 infectious disease Diseases 0.000 title description 11
- 150000001875 compounds Chemical class 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 12
- 208000019206 urinary tract infection Diseases 0.000 claims description 7
- KVBHJSYQSARJOY-UHFFFAOYSA-N 2-(4-bromophenyl)ethanimidamide;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.NC(=N)CC1=CC=C(Br)C=C1 KVBHJSYQSARJOY-UHFFFAOYSA-N 0.000 claims description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 239000000460 chlorine Chemical group 0.000 claims description 2
- 229910052801 chlorine Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 23
- 241001465754 Metazoa Species 0.000 description 20
- -1 acetamidine compound Chemical class 0.000 description 17
- 230000002421 anti-septic effect Effects 0.000 description 15
- 241000700159 Rattus Species 0.000 description 12
- 150000001409 amidines Chemical class 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- WJPKYOOURIMUTE-UHFFFAOYSA-N 2-(4-bromophenyl)ethanimidamide;hydrochloride Chemical compound Cl.NC(=N)CC1=CC=C(Br)C=C1 WJPKYOOURIMUTE-UHFFFAOYSA-N 0.000 description 10
- 210000001635 urinary tract Anatomy 0.000 description 10
- 210000003734 kidney Anatomy 0.000 description 9
- 241000124008 Mammalia Species 0.000 description 8
- 230000000845 anti-microbial effect Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 8
- 229960000210 nalidixic acid Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 241000588769 Proteus <enterobacteria> Species 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 210000003932 urinary bladder Anatomy 0.000 description 6
- 230000002485 urinary effect Effects 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- 230000004584 weight gain Effects 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 239000000083 urinary anti-infective agent Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000000721 bacterilogical effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 210000000626 ureter Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MFHFWRBXPQDZSA-UHFFFAOYSA-N 2-(4-bromophenyl)acetonitrile Chemical compound BrC1=CC=C(CC#N)C=C1 MFHFWRBXPQDZSA-UHFFFAOYSA-N 0.000 description 2
- UZAORPZGWBQCRV-UHFFFAOYSA-N 2-(4-bromophenyl)ethanimidamide Chemical compound NC(=N)CC1=CC=C(Br)C=C1 UZAORPZGWBQCRV-UHFFFAOYSA-N 0.000 description 2
- OQLZINXFSUDMHM-UHFFFAOYSA-N Acetamidine Chemical class CC(N)=N OQLZINXFSUDMHM-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 241000588770 Proteus mirabilis Species 0.000 description 2
- 241000588767 Proteus vulgaris Species 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- GDCXBZMWKSBSJG-UHFFFAOYSA-N azane;4-methylbenzenesulfonic acid Chemical compound [NH4+].CC1=CC=C(S([O-])(=O)=O)C=C1 GDCXBZMWKSBSJG-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000000244 kidney pelvis Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229940007042 proteus vulgaris Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- WHICEIACQGPSMU-UHFFFAOYSA-N 2-(4-bromophenyl)-n'-hydroxyethanimidamide Chemical compound ON=C(N)CC1=CC=C(Br)C=C1 WHICEIACQGPSMU-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- VFTGIEVLYNTGEZ-UHFFFAOYSA-N N'-hydroxy-2-phenylethanimidamide hydrochloride Chemical compound Cl.C1(=CC=CC=C1)CC(N)=NO VFTGIEVLYNTGEZ-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 238000003482 Pinner synthesis reaction Methods 0.000 description 1
- 208000022274 Proteus Infections Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010046607 Urine abnormality Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001539 anorectic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- JWWHXNCTBQKWNN-UHFFFAOYSA-N ethanimidamide 4-methylbenzenesulfonic acid Chemical compound CC(N)=N.CC1=CC=C(S(O)(=O)=O)C=C1 JWWHXNCTBQKWNN-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- AEXITZJSLGALNH-UHFFFAOYSA-N n'-hydroxyethanimidamide Chemical class CC(N)=NO AEXITZJSLGALNH-UHFFFAOYSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
- C07C259/14—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to hydrogen atoms or to acyclic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AR257907A AR205111A1 (es) | 1974-03-11 | 1975-01-01 | Un procedimiento para producir para - toluensulfonato de 2-(4-bromofenil) acetamidina |
| BE154034A BE826325A (fr) | 1974-03-11 | 1975-03-05 | Antiseptiques a base d'acetamidine destines aux voies urinaires |
| FR7507064A FR2302729A1 (fr) | 1974-03-11 | 1975-03-06 | Antiseptiques a base d'acetamidine destines aux voies urinaires |
| CA221,602A CA1033299A (en) | 1974-03-11 | 1975-03-07 | Acetamidine urinary antiseptics |
| GB9655/75A GB1491151A (en) | 1974-03-11 | 1975-03-07 | Urinary antiseptics |
| DE19752510325 DE2510325A1 (de) | 1974-03-11 | 1975-03-10 | Mittel zur prophylaxe und bekaempfung von harninfektionen |
| JP50028913A JPS51108035A (en) | 1974-03-11 | 1975-03-10 | Asetoamijinnyoroshodokuzai |
| US05/574,787 US3991210A (en) | 1974-03-11 | 1975-05-05 | Acetamidine urinary antiseptics |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44981374A | 1974-03-11 | 1974-03-11 | |
| FR7507064A FR2302729A1 (fr) | 1974-03-11 | 1975-03-06 | Antiseptiques a base d'acetamidine destines aux voies urinaires |
| CA221,602A CA1033299A (en) | 1974-03-11 | 1975-03-07 | Acetamidine urinary antiseptics |
| GB9655/75A GB1491151A (en) | 1974-03-11 | 1975-03-07 | Urinary antiseptics |
| DE19752510325 DE2510325A1 (de) | 1974-03-11 | 1975-03-10 | Mittel zur prophylaxe und bekaempfung von harninfektionen |
| JP50028913A JPS51108035A (en) | 1974-03-11 | 1975-03-10 | Asetoamijinnyoroshodokuzai |
| US05/574,787 US3991210A (en) | 1974-03-11 | 1975-05-05 | Acetamidine urinary antiseptics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2510325A1 true DE2510325A1 (de) | 1976-09-30 |
Family
ID=27560874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19752510325 Withdrawn DE2510325A1 (de) | 1974-03-11 | 1975-03-10 | Mittel zur prophylaxe und bekaempfung von harninfektionen |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JPS51108035A (enExample) |
| AR (1) | AR205111A1 (enExample) |
| BE (1) | BE826325A (enExample) |
| CA (1) | CA1033299A (enExample) |
| DE (1) | DE2510325A1 (enExample) |
| FR (1) | FR2302729A1 (enExample) |
| GB (1) | GB1491151A (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2833901A (en) * | 1999-10-06 | 2001-05-10 | Basf Aktiengesellschaft | Novel benzyl amidoxime derivatives, intermediate products and method for their production and use as fungicides |
-
1975
- 1975-01-01 AR AR257907A patent/AR205111A1/es active
- 1975-03-05 BE BE154034A patent/BE826325A/xx unknown
- 1975-03-06 FR FR7507064A patent/FR2302729A1/fr active Granted
- 1975-03-07 GB GB9655/75A patent/GB1491151A/en not_active Expired
- 1975-03-07 CA CA221,602A patent/CA1033299A/en not_active Expired
- 1975-03-10 JP JP50028913A patent/JPS51108035A/ja active Pending
- 1975-03-10 DE DE19752510325 patent/DE2510325A1/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| FR2302729B1 (enExample) | 1978-08-04 |
| FR2302729A1 (fr) | 1976-10-01 |
| JPS51108035A (en) | 1976-09-25 |
| CA1033299A (en) | 1978-06-20 |
| BE826325A (fr) | 1975-09-05 |
| GB1491151A (en) | 1977-11-09 |
| AR205111A1 (es) | 1976-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2226340C2 (enExample) | ||
| DE2858042C2 (de) | Rechtsdrehendes Isomer eines asymmetrischen Spirohydantoins sowie der Basensalze hiervon und ihre Verwendung | |
| EP0240829B1 (de) | Cancerostatisches Mittel | |
| DE69914084T2 (de) | Phenylacetylglutamin, phenylacetylisoglutamin, und/oder phenylacetat zur behandlung von neoplastischen erkrankungen | |
| DE2041771B2 (de) | derivate | |
| DE2646003A1 (de) | Amino-derivate der clavulansaeure, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel | |
| DE60108647T2 (de) | Zusamensetzungen mit schädlicher vasculärer wirkung | |
| DE2160148C2 (de) | Arzneimittel und bestimmte Sulfoxide als solche | |
| DE2263126A1 (de) | Durch einen cyklus mit 5 kohlenstoffatomen substituierte phenolderivate, deren herstellung und verwendung | |
| DE4340774A1 (de) | Moenomycin und dessen Derivate zur Herstellung von Arzneimitteln, sowie Arzneimittel mit einem Gehalt an Moenomycin oder dessen Derivaten | |
| EP1019055B1 (de) | Endothelin antagonist und betarezeptorenblocker als kombinationspräparate | |
| US3991210A (en) | Acetamidine urinary antiseptics | |
| DE3035688C2 (enExample) | ||
| EP1882476B1 (de) | Herstellung von antimikrobiellen Formulierungen unter Verwendung von 7-Oxa-2-thia 1,5-diazabicyclo[3.3.1]nonan-2,2-dion | |
| DE69318046T2 (de) | Antikrebsbenzaldehydverbindungen | |
| DE2510325A1 (de) | Mittel zur prophylaxe und bekaempfung von harninfektionen | |
| DE69519581T2 (de) | Guanidylmethyl cyclohexancarbonsäure ester derivate | |
| DE3240650C2 (enExample) | ||
| CH643814A5 (de) | Hydroxamsaeureverbindungen, verfahren zu deren herstellung sowie diese verbindungen enthaltende medikamente. | |
| DE10356409B4 (de) | Neues Arzneimittel Oxachelin und Derivate | |
| DE3347658A1 (de) | 1.4-naphthochinonderivate mit entzuendungshemmender wirkung | |
| DE2800755A1 (de) | 1-eckige klammer auf 2-(halogenphenylthio)-4-(p-chlor- oder -fluorphenyl)-n-butyl eckige klammer zu -imidazole und ihre herstellung | |
| EP0485890A2 (de) | Verwendung von 2,3-disubstituierten 1-Azolyl-propanen als Wachstumshemmer der pathogenen Phase dimorpher Hefezellen | |
| DE2428294A1 (de) | Mercaptomethylpyridine und derivate derselben | |
| DE69528922T2 (de) | Herstellung von 2-Bromo-5-(2-bromo-2-nitro-vinyl)-furan und deren Verwendung als Microzide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8141 | Disposal/no request for examination |